HAVANA, June 27- Some 21,000 people suffering diabetic foot ulcers (DFU) have been treated in Cuba with Heberprot-P, considered the only alternative to prevent the amputation of extremities in patients with terminal injuries.
Almost six years after the comprehensive care program to treat patients with DFU with Heberprot-P started (June 30, 2007), results are favourable, according to areport provided by the Center for Genetic Engineering and Biotechnology (CIGB).
In an article published by the magazine Advance Pharmacoepidemiology & Drug Safety, 2013, researchers revealed there is a 75 percent probability of response of complete granulation, 61 percent of cicatrisation and the reduction of relative risk of amputation is of 71 percent.
They also said that no serious adverse effect could be attributed to the use of Heberprot-P.
The new product developed by the CIGB, with recombinant growth factor as its active principle, is injected in and around the lesions and has changed the lives of many patients.
-BERNAMA
